---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001840"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:34:38.184143+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Virios Therapeutics cuts cash compensation 10%; grants stock options to officers and directors

## Summary
- Board approved 10% salary reduction for all employees including executive officers, effective March 1, 2024.
- Non-employee director cash compensation also reduced by 10%.
- Stock options granted to executive officers and directors: CEO Greg Duncan receives 138,835 options; total 410,570 options across 10 recipients.
- Options have exercise price of $0.357/share and vest on February 26, 2025.

## SEC filing metadata
- accession: 0001558370-24-001840
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024001840/0001558370-24-001840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024001840/tmb-20240226x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001840
- JSON: https://secwatch.observer/filing/0001558370-24-001840.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.